Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $1.73M rose 14.8% year over year, behind the +54.6% change in trailing-twelve-month revenue. Sequentially, it fell 73.9% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $8.73M (-40.1%) for the fiscal year ending Dec 2026, a slowdown from the +53.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.73M-73.9% QoQ
Last fiscal yearDec 2025
$14.56M+53.2% YoY
LTMMar 2026
$14.78M+54.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.8%-33.4%-48.2 pp
1 year+53.2%-40.1%-93.3 pp
3-year CAGR-0.3%+59.9%+60.2 pp
5-year CAGR+103.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
14.56M USD
Year-over-year change
+53.2%
4-year CAGR
+39.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 revenue of $14.78M is the 3rd highest of the 4 companies compared; the peer median is $26.55M.
  • Its year-over-year change of +54.6% is the 2nd highest of 4, against a peer median of -51.0%.
  • Over three fiscal years its annual growth of -0.3% compares with a peer median of +152.5%.
LCTX Competitors Peer median
Revenue for LCTX and competitors
Company Period LTM YoY 3-year CAGR
MESOMesoblast LimitedLTM Jun 2026$120.25M +599.2%+152.5%
CELUCelularity Inc.LTM Dec 2025$26.55M -51.0%+13.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$14.78M +54.6%-0.3%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 -100.0%+175.9%
Peer median (excluding LCTX) $26.55M-51.0%+152.5%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.